1. 172 Secukinumab 150 mg provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: three-year results from Phase 3 trial, MEASURE 2. (25th April 2018) Authors: Tahir, Hasan; Marzo-Ortega, Helena; Legerton, Clarence W; Sieper, Joachim; Kivitz, Alan; Blanco, Ricardo; Cohen, Martin; Delicha, Evie Maria; Rohrer, Susanne; Richards, Hanno B Journal: Rheumatology Issue: Volume 57(2018)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 261 Secukinumab 150 mg provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 4-year results from the Phase 3 trial, MEASURE 2. (12th April 2019) Authors: Marzo-Ortega, Helena; Sieper, Joachim; Kivitz, Alan; Blanco, Richardo; Cohen, Martin; Delicha, Eumorphia-Maria; Rohrer, Susanne; Richards, Hanno Journal: Rheumatology Issue: Volume 58(2019)Supplement 3 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the phase 3 MEASURE 2 trial. (June 2020) Authors: Marzo-Ortega, Helena; Sieper, Joachim; Kivitz, Alan J; Blanco, Ricardo; Cohen, Martin; Pavelka, Karel; Delicha, Eumorphia M; Stefanska, Anna; Richards, Hanno B; Rohrer, Susanne Journal: Lancet Issue: Volume 2:Number 6(2020) Page Start: e339 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. FRI0379 LONG-TERM EVALUATION OF SECUKINUMAB 150 MG IN ANKYLOSING SPONDYLITIS: 5-YEAR END-OF-STUDY EFFICACY AND SAFETY RESULTS FROM A PHASE 3 TRIAL. (June 2019) Authors: Marzo-Ortega, Helena; Sieper, Joachim; Kivitz, Alan; Blanco, Ricardo; Cohen, Martin; Pavelka, Karel; Delicha, Eumorphia Maria; Stefanska, Anna; Richards, Hanno; Rohrer, Susanne Journal: Annals of the rheumatic diseases Issue: Volume 78(2019)Supplement 2 Page Start: 873 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P248 Subcutaneous secukinumab 150 mg provides rapid and sustained relief in total and nocturnal back pain, morning stiffness and fatigue in patients with active AS over 4 years. (20th April 2020) Authors: Marzo-Ortega, Helena; Miceli-Richard, Corinne; Gill, Sonja; Magery, Marina; Machado, Paula G. P; Shete, Abhijit; Wang, Jianyuan; Rohrer, Susanne; Deodhar, Atul Journal: Rheumatology Issue: Volume 59(2020)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella dysenteriae type 1 administered to healthy adults: A single blind, partially randomized Phase I study. Issue 36 (26th August 2015) Authors: Hatz, Christoph F.R; Bally, Bettina; Rohrer, Susanne; Steffen, Robert; Kramme, Stefanie; Siegrist, Claire-Anne; Wacker, Michael; Alaimo, Cristina; Fonck, Veronica Gambillara Journal: Vaccine Issue: Volume 33:Issue 36(2015) Page Start: 4594 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella dysenteriae type 1 administered to healthy adults: A single blind, partially randomized Phase I study. Issue 36 (26th August 2015) Authors: Hatz, Christoph F.R; Bally, Bettina; Rohrer, Susanne; Steffen, Robert; Kramme, Stefanie; Siegrist, Claire-Anne; Wacker, Michael; Alaimo, Cristina; Fonck, Veronica Gambillara Journal: Vaccine Issue: Volume 33:Issue 36(2015) Page Start: 4594 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3‐Year Results from the Phase 3 MEASURE 3 Study. Issue 2 (20th January 2020) Authors: Pavelka, Karel; Kivitz, Alan J.; Dokoupilova, Eva; Blanco, Ricardo; Maradiaga, Marco; Tahir, Hasan; Wang, Yi; Porter, Brian O.; Stefanska, Anna; Richards, Hanno B.; Rohrer, Susanne Journal: ACR open rheumatology Issue: Volume 2:Issue 2(2020) Page Start: 119 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double‐Blind, Active Comparator– and Placebo‐Controlled Study. Issue 6 (3rd May 2017) Authors: Blanco, Francisco J.; Möricke, Rüdiger; Dokoupilova, Eva; Codding, Christine; Neal, Jeffrey; Andersson, Mats; Rohrer, Susanne; Richards, Hanno Journal: Arthritis & rheumatology Issue: Volume 69:Issue 6(2017) Page Start: 1144 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2. Issue 2 (28th December 2017) Authors: Marzo-Ortega, Helena; Sieper, Joachim; Kivitz, Alan; Blanco, Ricardo; Cohen, Martin; Delicha, Evie-Maria; Rohrer, Susanne; Richards, Hanno Journal: RMD open Issue: Volume 3:Issue 2(2017) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗